The drugmaker posted a 3.3% rise in net profit to ₹566 crore for the quarter ended June, while revenue surged 54.8% year-on-year to ₹4,921 crore. Operating performance remained robust, with EBITDA climbing 61.2% to ₹1,664 crore, helping margins improve to 33.8% from 32.5% a year earlier.
Ahead of the earnings announcement, Torrent Pharmaceuticals’ shares ended Thursday’s session at ₹4,890 on the NSE.
The company’s India business continued to outperform the broader pharmaceutical market. Domestic revenues rose to ₹2,157 crore, growing 19% against the Indian Pharmaceutical Market’s (IPM) 12% growth, according to the AIOCD PharmaTrac dataset.
Torrent also strengthened its leadership in the cardiovascular segment, becoming the No. 1 player in the Indian cardiac market. Another highlight was the company’s generic Semaglutide portfolio, which captured a 36% market share across oral and injectable formulations during the first quarter of FY27.
The US business also delivered a healthy performance, with revenues increasing 36% to ₹418 crore. On a constant currency basis, revenue rose 23%, aided by recent product launches achieving targeted market share and certain one-off opportunities.
Brazil remained another growth driver, with revenues rising 27% to ₹277 crore. Although constant currency growth was more modest at 3%, Torrent significantly outperformed the local market, registering 21% growth against industry growth of 5%, supported by key brands and recent launches. The company currently has 58 products awaiting approval from Brazilian regulator ANVISA.
Management noted that Brazil’s reported growth was affected by a one-time channel inventory reduction after distributors sought extended credit periods amid higher borrowing costs. Secondary sales, however, continued to reflect healthy underlying demand.
Germany remained the only major weak spot during the quarter. Revenue from the market increased 3% in rupee terms but declined 9% in constant currency, as supply disruptions at a third-party supplier and lower tender offtake continued to weigh on performance.
Torrent’s broader international business, comprising the US, emerging markets and contract development and manufacturing (CDMO), also maintained steady momentum. Revenue from these operations rose 12%, while the CDMO business posted a 27% increase during the quarter, adding another growth lever to the company’s diversified portfolio.
